We report heterozygous mutations in the genes encoding either type I or type II transforming growth factor b receptor in ten families with a newly described human phenotype that includes widespread perturbations in cardiovascular, craniofacial, neurocognitive and skeletal development. Despite evidence that receptors derived from selected mutated alleles cannot support TGFb signal propagation, cells derived from individuals heterozygous with respect to these mutations did not show altered kinetics of the acute phase response to administered ligand. Furthermore, tissues derived from affected individuals showed increased expression of both collagen and connective tissue growth factor, as well as nuclear enrichment of phosphorylated Smad2, indicative of increased TGFb signaling. These data definitively implicate perturbation of TGFb signaling in many common human phenotypes, including craniosynostosis, cleft palate, arterial aneurysms, congenital heart disease and mental retardation, and suggest that comprehensive mechanistic insight will require consideration of both primary and compensatory events.
The TGFbs are a family of multipotential cytokines that influence diverse cellular fates including proliferation, migration, synthetic repertoire and death 1, 2 . Although targeted perturbations of TGFb signaling in model systems have demonstrated its essential role in diverse developmental and homeostatic processes, there are few examples of genetically defined human pathologic correlates 3 . In theory, this could reflect either a survival dependency on or extensive functional redundancy in TGFb-regulated programs. It has been proposed that heterozygous loss-of-function mutations in the gene (TGFBR2) encoding type II transforming growth factor b receptor (TbRII) phenocopy Marfan syndrome (MFS) 4 , a connective tissue disorder caused by deficiency of the extracellular matrix protein fibrillin-1 (ref. 5) . It was also proposed that heterozygous mutations in TGFBR2 are clinically expressed as a decrease in TGFb signaling 4 rather than an increase, as observed in certain tissues of mice deficient for fibrillin-1 (refs. 6,7).
We describe ten families with a new aortic aneurysm syndrome characterized by widely spaced eyes (hypertelorism), bifid uvula and/ or cleft palate, and generalized arterial tortuosity with ascending aortic aneurysm and dissection (Figs. 1a and 2a and Table 1 ). This syndrome shows autosomal dominant inheritance and variable clinical expression (Figs. 1b and 2b) . Other findings in multiple systems ( Table 1 and Supplementary Note online) include craniosynostosis, structural brain abnormalities, mental retardation, congenital heart disease and aneurysms with dissection throughout the arterial tree.
We considered TGFBR2 as a candidate gene because TGFb signaling has a prominent role in vascular and craniofacial development in mouse models 8, 9 and because conditional knockout of TGFBR2 in neural crest cells causes cleft palate and calvaria defects 10 . We sequenced all exons of TGFBR2 and identified heterozygous mutations in six of ten families (Fig. 1b) . Five were missense mutations affecting evolutionarily conserved residues in the kinase domain of TbRII and related receptors (Y336N, A355P, G357W, R528H and R528C; Fig. 1b,c) . R528H was previously reported as a somatic event in colon cancer and was shown to cause loss of function in a transient transfection assay 11 . Three missense mutations were found in isolated cases and were not observed in the unaffected parents (Fig. 1b) . The two other missense mutations segregated with the phenotype in small families and were absent in 100 control chromosomes (Fig. 1b and data not shown). The sixth mutation occurred in an individual with sporadic disease and affects the invariant A at the À2 position of the splice acceptor sequence in intron 1 (Fig. 1b) . This mutation induces use of a cryptic splice acceptor in exon 2 that results in the in-frame skipping of nucleotides 95-112 (observed in four of nine subcloned and sequenced RT-PCR amplicons) and deletion of residues 32-37 in the extracellular domain of TbRII ( Supplementary Fig. 1 online) .
We did not find any mutations in TGFBR2 in the four other families with a clinically indistinguishable phenotype ( Table 1 and Fig. 2a) . We sequenced all exons of TGFBR1 and found a unique missense mutation in each family (families 7-10) that affected evolutionarily conserved residues in type I transforming growth factor b receptor (TbRI; Fig. 2b,c) . Two missense mutations (M318R and D400G) occurred in the kinase domain, one mutation (T200I) occurred at the junction of the glycine-serine-rich domain and the kinase domain, and one mutation (R487P) occurred just past the kinase domain at the C terminus of TbR1 (Fig. 2c) . Substitution of the threonine at residue 200 (T200V or T200D) caused loss of TbRI function in a transient transfection assay 12 . The mutations in families 7-9 occurred de novo, whereas mutation R487P segregated with disease in family 10 and was absent in 100 control chromosomes (Fig. 2b and data not shown).
Histologic analysis showed loss of elastin content and disarrayed elastic fibers in the aortic media of individuals with classic MFS or mutations in TGFBR2 compared with samples from age-matched controls (Fig. 3a) . Ultrastructural analysis showed loss of intimate spatial association between elastin deposits and vascular smooth muscle cells (Fig. 3b) . We observed these characteristics in young children and in the absence of inflammation, suggestive of a severe defect in elastogenesis rather than secondary elastic fiber destruction. In addition, we observed a marked excess of aortic wall collagen in individuals with MFS compared with age-matched controls; this collagen excess was accentuated in individuals with mutations in TGFBR2 (Fig. 3a) . As multiple collagens normally expressed in the aorta are derived from early-induced TGFb target genes (including COL1A1 and COL3A1), these data are consistent with increased (rather than decreased) TGFb signaling 13 .
To assess the in vivo consequences of heterozygous mutations, which occur in the context of expression of wild-type TbRI or TbRII from the normal allele, we studied the acute-phase response of primary dermal fibroblasts to exogenous TGFb1 by monitoring the activation (phosphorylation) status of Smad2, an essential mediator of TGFb signaling. We exposed four fibroblast lines from affected individuals with mutations of TbRI or TbRII to recombinant TGFb1 after a 24-h period of serum deprivation. These lines showed a normal rate and level of phosphorylation of Smad2 compared with three cell passage number-matched fibroblast lines from age-matched controls (Fig. 4a,b) . There is direct (R528H) or indirect (T200I) evidence that two of the studied mutant receptors lack the ability to propagate TGFb signal when expressed in a cell line naive for TbRII (refs. 11,12) . These data show that acute responsiveness is preserved in cells heterozygous with respect to loss-of-function mutations of TGFb receptors and effectively exclude the possibility that the phenotype of the affected individuals results from either potent dominant-negative interference or gain of function by representative mutant receptors.
To determine the chronic consequence of heterozygous mutations of TGFb receptors, we assessed the amount of nuclear phosphorylated Smad2 in the aortic wall. We observed increased signal intensity for nuclear phosphorylated Smad2 in both individuals with classic MFS (MFS1) and two individuals with mutations in TGFBR2 compared with control samples (Fig. 4c) . Samples from affected individuals also showed increased expression of connective tissue growth factor (CTGF), which derives from a prototypical TGFb-responsive gene with defined Smad-dependent promoter elements 14 (Fig. 4d) . Together with increased collagen expression (Fig. 3a) , these data are suggestive of enhanced, rather than repressed, TGFb signaling in the presence of heterozygous mutations of TbRII and in contexts relevant to the performance of cells during tissue development and homeostasis in vivo.
Some individuals with mutations in TGFBR1 or TGFBR2 have phenotypes that overlap somewhat with MFS, but none met the diagnostic criteria for MFS 15 . All affected individuals had manifestations in multiple organ systems that are not associated with MFS ( Table 2) . In these individuals, aneurysms tend to be particularly aggressive and to rupture at an early age (e.g., individuals 4.II-1 and 5.II-1) or be of a size not associated with high risk in MFS 16 (e.g., individual 1.II-1). Therefore, from a management perspective, the distinction from MFS is neither ambiguous nor unimportant. Comprehensive mutation analysis of fibrillin-1 in 93 consecutive individuals referred with classic MFS identified 86 mutations 17 . We sequenced TGFBR1 and TGFBR2 in the other seven individuals and found no mutations (data not shown).
At the extreme of clinical severity, some individuals with mutations in TGFBR1 or TGFBR2 have phenotypes that overlap considerably with the Marfanoid craniosynostosis syndrome (called ShprintzenGoldberg syndrome, SGS). SGS is not associated with cleft palate, arterial tortuosity or risk of aneurysm or dissection other than at the aortic root, and most affected individuals have no vascular pathology ( Table 2) 18 . Sequencing of TGFBR1 and TGFBR2 in five individuals with classic SGS identified no mutations (data not shown). Nevertheless, given the extent of phenotypic overlap between SGS, MFS and selected individuals with mutations in either TGFBR1 or TGFBR2, the pathogenesis of SGS probably also relates to alteration in TGFb signaling.
Microfibrils composed of fibrillin-1 or fibrillin-2 bind the large latent complex of TGFb, selected bone morphogenetic proteins (BMPs) and perhaps other members of the TGFb superfamily 19, 20 . Excess TGFb signaling correlates with both lung and heart valve pathology in fibrillin-1-deficient mice, and the phenotypes can be rescued by TGFb antagonism in vivo 6, 7 . In contrast, there is synergism between fibrillin-2 and BMP7 deficiency in clinical expression of digit abnormalities 21 . The emerging view is that the fibrillins negatively regulate TGFb activation but also positively regulate signaling by concentration of selected cytokines at the sites of intended function 22 . Thus, microfibrillar disorders such as MFS may represent the sum of diverse primary and compensatory events elicited by both positive and negative dysregulation of multiple cytokines.
Results of transient transfection studies in cells naive for TbRII indicated that the previously reported mutations in TGFBR2 caused loss of function and that the resultant MFS-like phenotype is caused by decreased TGFb signaling 4 . We reasoned that this experimental design failed to mimic the situation in affected individuals, where cells are expressing both functional and nonfunctional TbRII. The regulation of TGFb signaling is complex, with auto-and cross-regulation of ligands and their receptors 2, 23 . Such events might culminate in excess, rather than decreased, TGFb superfamily signaling. This hypothesis was bolstered by the observation that transgenic mice expressing a dominant-negative (kinase domain-deleted) TbRII showed tissue fibrosis, upregulation of TGFb ligands, increased expression of TGFb-responsive genes and increased responsiveness to exogenous ligand 24, 25 . We now present evidence that a similar net effect can be 
+, present; À, absent; blank, unknown; *, deceased. cytokine signaling and disease pathogenesis is difficult to predict and may vary in a context-and genotype-specific manner. These issues will be best addressed using TGFb receptor-deficient animal models.
In summary, our data identify the crucial contribution of TGFb signaling to diverse developmental and homeostatic processes and provide definitive proof of its role in the pathogenesis of many common human phenotypes. They also show that isolated consideration of the obvious proximal consequence of a given perturbation may be inadequate to achieve comprehensive mechanistic insight. Rather, many alterations in the complex processes of TGFb secretion, localization, activation and signaling probably have diverse consequences for the microenvironments in which morphogenetic events take place.
METHODS
Subjects and clinical evaluation. This study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine. We obtained informed consent from all subjects involved in the study and specific consent for the publication of photographs that show identity. Detailed clinical descriptions of the families are provided in Supplementary Note online.
Mutation analysis. We amplified genomic DNA by PCR using primers in the flanking introns of TGFBR1 and TGFBR2 (primer sequences available on request). We carried out sequence analysis using an Applied Biosystems automated DNA sequencer and protocols provided by the manufacturer. For individuals with seemingly sporadic disease, we sequenced both parents' DNA, when available. We used paternity testing to confirm the association between de novo mutation and sporadic disease. All mutations showing familial segregation were not found in a panel of at least 100 control chromosomes. We carried out family and population screening by virtue of the loss of a restriction site for RsaI or AciI for mutation Y366N or R487P, respectively. For mutation A355P, we carried out screening by allele-specific PCR using primers (sequences available on request) that allowed specific amplification of the mutant sequence from genomic DNA using an annealing temperature of 56 1C.
Cell culture. We derived fibroblast cultures from skin biopsies on the forearm. We cultured cells in minimal essential medium with 15% fetal bovine serum in the presence of antibiotics and passaged them at confluence. Cells from affected individuals and controls were matched for early passage number (o5). We assessed TGFb responsiveness by adding recombinant TGFb1 (R&D Systems; 5 ng ml À1 ) to the media of cells that had been deprived of serum for 24 h. We collected protein immediately, 15 min, 30 min, 1 h and 4 or 6 h after addition of TGFb1.
Western-blot analysis. We carried out western-blot analysis as previously described 6 . For studies examining the phosphorylation status of effectors of TGFb signaling, we extracted protein in mammalian protein extraction (M-Per) buffer (Pierce) after adding the protein phosphatase inhibitor set in accordance with the manufacturer's instructions (Upstate). Antibodies used in this study were directed against GAPDH (Santa Cruz Biotechnology), Smad2 and pSmad2 (Cell Signaling Technology). We repeated these analyses on multiple lysates with comparable results. We quantified immunoblot signals using the Quantity One package of analysis software (Bio-Rad).
Light and electron microscopy. We obtained aortic samples from the sinuses of Valsalva of affected individuals at the time of surgery. We obtained control samples from young individuals (o22 years) after death from a cause unrelated to aortic disease. We stained aortic sections with VerhoeffVan Giesen (for elastin) and Mason's trichrome (for collagen) stains. We analyzed immunohistochemistry using antibodies directed against phosphorylated Smad2 and CTGF (Cell Signaling Technology and Abcam, respectively) and previously described methods 6 . We carried out electron microscopy as previously described 6 .
GenBank accession numbers. TGFBR2 cDNA, NM_003242; TGFBR2 coding region, NT_022517; TGFBR1 cDNA, NM_004612; TGFBR1 coding region, NT_086754.
Note: Supplementary information is available on the Nature Genetics website. 
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